We showed that systemic delivery of in vitro differentiated murine M(IL4)s significantly reduced the severity of dinitrobenzene sulphonic acid (DNBS), oxazolone, and dextran sodium sulphate (DSS) induced colitis in mice: in contrast, the administration of CAMs differentiated in vitro with IFNγ [or control M(0)] did not impact the outcome of the colitic disease (12–14). This evidence concerns the gene IL4 and colitis.